Clinical trial · Interventional
SCG142 TCR-T Cells for Human Papillomavirus-Associated Carcinomas
A Phase 1 Clinical Study of Autologous TCR-T Cells (SCG142) Therapy for Advanced HPV Associated Carcinomas
NCT06544720CI-TRIAL-00079640recruitingPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
A multicenter, open, single arm dose escalation and dose expansion phase I study to evaluate the safety, tolerability, and efficacy of SCG142 TCR-T cells in Subjects with advanced HPV associated carcinomas.
Conditions
Conditions (8)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Anal Cancer | Malignant Anal Neoplasm | CURATED_EXACT | 0.92 |
| Cervical Cancer | Malignant Cervical Neoplasm | CURATED_EXACT | 0.92 |
| Head and Neck Cancers | Malignant Head and Neck Neoplasm | ALIAS | 0.90 |
| HPV-Related Malignancy | Human Papillomavirus-Related Malignant Neoplasm | ALIAS | 0.90 |
| Human Papillomavirus Associated Carcinomas | — | UNRESOLVED | — |
| Penile Cancer | Malignant Penile Neoplasm | CURATED_EXACT | 0.92 |
| Vaginal Cancer | Malignant Vaginal Neoplasm | CURATED_EXACT | 0.92 |
| Vulva Cancer | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| SCG142 TCR-T cells | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- SCG142 TCR-T cells
- description
- Monotherapy of SCG142
- interventionNames
- Biological: SCG142 TCR-T cells
Primary outcomes (1)
- measure
- DLT
- timeFrame
- 28 days
- description
- Number of subjects with adverse events (AEs) and laboratory abnormalities defined as dose limiting toxicities (DLT)
Secondary outcomes (1)
- measure
- Efficacy: antitumor activity of SCG142
- timeFrame
- 2 years
- description
- Assessed by RECIST 1.1 and iRECIST
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Key Inclusion Criteria: 1. Greater than or equal to 18 years of age 2. HPV associated carcinomas 3. Patients must have at least one measurable lesion defined by RECIST 1.1 4. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 Key Exclusion Criteria: 1. Active or uncontrollable infections or other active major medical illnesses of the cardiovascular, respiratory. 2. Patients with active autoimmune diseases. 3. Patient has a known active Hepatitis B or Hepatitis C. 4. Other severe medical conditions that may limit subject\'s participation in this trial.
References
Publications (0)
Data not yet available
No reference posted for this study.